UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Is this really thalassemia?

American journal of hematology, 2023-11, Vol.98 (11), p.1814-1815

2023

Volltextzugriff (PDF)

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Blood, 2021-11, Vol.138 (Supplement 1), p.1201-1201

2021

Volltextzugriff (PDF)

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Blood, 2018-11, Vol.132 (Supplement 1), p.1774-1774

2018

Volltextzugriff (PDF)

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Blood, 2012-12, Vol.120 (25), p.5084-5085

2012

Volltextzugriff (PDF)

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Blood, 2017-12, Vol.130, p.2918-2918

2017

Volltextzugriff (PDF)

Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available

Leukemia & lymphoma, 2019-12, Vol.60 (14), p.3493-3502

2019

Volltextzugriff (PDF)

From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia

Annales de biologie clinique (Paris), 2017-12, Vol.75 (6), p.689-694

2017

Volltextzugriff (PDF)

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Blood, 2012-11, Vol.120 (21), p.422-422

2012

Volltextzugriff (PDF)

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Blood, 2011-11, Vol.118 (21), p.972-972

2011

Volltextzugriff (PDF)

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Blood, 2010-11, Vol.116 (21), p.976-976

2010

Volltextzugriff (PDF)

Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program

Blood, 2009-11, Vol.114 (22), p.1054-1054

2009

Volltextzugriff (PDF)

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program

Blood, 2009-11, Vol.114 (22), p.2764-2764

2009

Volltextzugriff (PDF)

Is this really thalassemia?

American journal of hematology, 2023, Vol.98 (11), p.1814-1815

2023

Volltextzugriff (PDF)

CALM-AF10 Positive Acute Myeloid Leukemias: A French Cohort of 18 Patients

Blood, 2008-11, Vol.112 (11), p.1496-1496

2008

Volltextzugriff (PDF)

Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9

Genes chromosomes & cancer, 2006-06, Vol.45 (6), p.575-582

2006

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)
Berichte
(1)

Sprache

Englisch
(25)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Hematology
(6)
Life Sciences
(3)
Follow-Up Studies
(2)
Human Health And Pathology
(2)
Humans
(2)
Medical Prognosis
(2)
Oncology
(2)
Aberrations Chromosomiques
(1)
Adolescent
(1)
Antimetabolites, Antineoplastic - Therapeutic Use
(1)
Azacitidine
(1)
Azacitidine - Therapeutic Use
(1)
Blood Cell Count
(1)
Bone Marrow - Metabolism
(1)
Cancer
(1)
Chromatography
(1)
Chromosome 7
(1)
Chromosome 7 Abnormalities
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

Is this really thalassemia?

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available

Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM)

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program

Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program

Is this really thalassemia?

Treatment of Lower Risk MDS with Del 5q by Lenalidomide, with or without G-CSF: Current Results of the French Patient Named Program (ATU)

CALM-AF10 Positive Acute Myeloid Leukemias: A French Cohort of 18 Patients

Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9

Aktive Filter

Suchergebnisse filtern